Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Human epicardial adipose tissue is a source of inflammatory mediators.Circulation. 2003; 108: 2460-2466
- The double role of epicardial adipose tissue as pro- and anti-inflammatory organ.Horm Metab Res. 2008; 40: 442-445
- Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives.Eur J Echocardiog. 2009; 10: 549-555
- Relationship of epicardial adipose tissue by echocardiography to coronary artery disease.Heart. 2008; 94: 97
- Subepicardial adipose tissue and the presence and severity of coronary artery disease.Atherosclerosis. 2006; 186: 354-359
- Increase in epicardial fat volume is associated with greater coronary artery calcification progression in subjects at intermediate risk by coronary calcium score: a serial study using non-contrast cardiac CT.Atherosclerosis. 2011; 218: 363-368
- Epicardial fat and its association with cardiovascular risk: a cross-sectional observational study.Heart Views. 2010; 11: 103-108
- The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).Am J Clin Nutr. 2009; 90: 499-504
- Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension. 2003; 42: 1206-1252
- Echocardiographic epicardial fat: a review of research and clinical applications.J Am Soc Echocardiogr. 2009; 22: 1311-1319
- Evaluation of a new air displacement plethysmography for measuring human body composition.Med Sci Sports Exerc. 1995; 27: 1686-1691
- Comparison of air-displacement plethysmography, hydrodensitometry, and dual x-ray absorptiometry for assessing body composition of children 10 to 18 years of age.Ann N Y Acad Sci. 2000; 904: 72-78
- History of the Rochester Epidemiology Project.Mayo Clin Proc. 1996; 71: 266-274
- Adipose tissue of atrial septum as a marker of coronary artery disease.Chest. 2007; 132: 817-822
- Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease.Nutr Metab Cardiovasc Dis. 2009; 19: 211-217
- Epicardial fat: an additional measurement for subclinical atherosclerosis and cardiovascular risk stratification?.J Am Soc Echocardiogr. 2011; 24: 339-345
- Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status.Am J Physiol Endocrinol Metab. 2007; 293: 1443-1450
- Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data.J Am Coll Cardiol. 2011; 57: 1877-1886
- The obesity paradox, weight loss, and coronary disease.Am J Med. 2009; 122: 1106-1114
- Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease.Eur Heart J. 2007; 28: 2087-2093
- Epicardial adipose tissue relating to anthropometrics, metabolic derangements and fatty liver disease independently contributes to serum high-sensitivity C-reactive protein beyond body fat composition: a study validated with computed tomography.J Am Soc Echocardiogr. 2012; 25: 234-241
- Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction.JAMA. 2011; 306: 2120-2127
- Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk.J Clin Endocrinol Metab. 2003; 88: 5163-5168
- Relationship of epicardial fat thickness and fasting glucose.Int J Cardiol. 2008; 128: 424-426
- Threshold values of high-risk echocardiographic epicardial fat thickness.Obesity. 2008; 16: 887-892
This work was supported in part by the Mayo Clinic Clinician-Investigator Training Program and Mayo Foundation (Rochester, Minnesota).
Dr. Somers has served as a consultant to Respironics (Andover, Massachusetts), ResMed (San Diego, California), Cardiac Concepts (Minnetonka, Minnesota), GlaxoSmithKline (Philadelphia, Pennsylvania), Sepracor (Marlborough, Massachusetts), and Medtronic Corporation (Fridley, Minnesota) and has been a principal investigator or co-investigator on research with grants funded by the Respironics Foundation (Andover, Massachusetts), ResMed Foundation (San Diego, California), and Sorin Corporation (Arvada, Colorado).